Abstract
Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.
Original language | English (US) |
---|---|
Article number | 100546 |
Journal | Gynecologic Oncology Reports |
Volume | 32 |
DOIs | |
State | Published - May 2020 |
Externally published | Yes |
Keywords
- AKT inhibitor
- MK-2206
- PI3K/AKT pathway
- PTEN
- Platinum resistant ovarian cancer
- Serous ovarian carcinoma
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology